An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
Latest Information Update: 03 Nov 2023
Price :
$35 *
At a glance
- Drugs Sebelipase alfa (Primary)
- Indications Wolman disease
- Focus Registrational; Therapeutic Use
- Acronyms VITAL
- Sponsors Alexion Pharmaceuticals; Synageva BioPharma
- 10 Jan 2019 Status changed from active, no longer recruiting to completed.
- 10 Jan 2019 Status changed from active, no longer recruiting to completed.
- 12 Mar 2018 The study has been completed in Ireland (end dare: 2018-01-03).